Harald Kramer1, Val M. Runge2, L Gill Naul2, Alan T. Loynachan3, Maximilian F. Reiser1, Bernd J. Wintersperger1
1Department of Clinical Radiology, University Hospital Munich, Munich, Germany; 2Scott and White Memorial Hospital, TX, United States; 3University of Kentucky, KY, United States
The detection of a link between the application of Gd contrast agents highlights the need for dedicated application protocols. The purpose of the study was to evaluate the efficacy of single dose gadobutrol compared to a substantially higher dose gadoterate meglumine in a tumor model at 1.5T and 3.0T. All animals were implanted Glioma cells using an implanted plastic brain cannula. After 7 days brain MR exams were performed whether with gadobutrol or gadoterate meglumine with a 24h interval. After the second MRI brains harvested for histopathologic assessment. Data were evaluated regarding SNR, CNR and lesion enhancement (LE).